This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
TCR2 Therapeutics Dividende
Dividende contrôle des critères 0/6
TCR2 Therapeutics does not have a record of paying a dividend.
Informations clés
n/a
Rendement du dividende
n/a
Ratio de distribution
Rendement moyen de l'industrie | 1.9% |
Prochaine date de paiement du dividende | n/a |
Date ex-dividende | n/a |
Dividende par action | n/a |
Résultat par action | -US$4.15 |
Prévision de rendement du dividende | n/a |
Mises à jour récentes des dividendes
Pas de mise à jour
Recent updates
Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely
Mar 08Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?
Nov 23TCR² Therapeutics: Betting On A Solid Reversal
Aug 18TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
Aug 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully
Jun 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth
Jan 11TCR2 Therapeutics: Trading Below Cash
Jan 06TCR2 Therapeutics: Trading Near Cash Value
Oct 12Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?
Sep 02TCR2 Therapeutics - Promising Technology And Upside Potential
Jun 15Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
Jun 04Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
Feb 19TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
Dec 28TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210
Dec 14TCR2 Therapeutics reports Q3 results
Nov 12TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity
Nov 10Stabilité et croissance des paiements
Récupération des données sur les dividendes
Dividende stable: Insufficient data to determine if TCRR's dividends per share have been stable in the past.
Dividende croissant: Insufficient data to determine if TCRR's dividend payments have been increasing.
Rendement des dividendes par rapport au marché
TCR2 Therapeutics Rendement des dividendes par rapport au marché |
---|
Segment | Rendement du dividende |
---|---|
Entreprise (TCRR) | n/a |
25% du marché (US) | 1.4% |
25% du marché (US) | 4.3% |
Moyenne du secteur (Biotechs) | 1.9% |
Analyste prévisionnel (TCRR) (jusqu'à 3 ans) | n/a |
Dividende notable: Unable to evaluate TCRR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Dividende élevé: Unable to evaluate TCRR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Bénéfice distribué aux actionnaires
Couverture des revenus: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Paiement en espèces aux actionnaires
Couverture des flux de trésorerie: Unable to calculate sustainability of dividends as TCRR has not reported any payouts.